Japan was ranked as the second largest branded pharmaceutical market and the second largest CNS market globally as well in 2020. It has the world's oldest population with almost 29% of people over the age of 65. This trend is expected to increase over the next 10-20 years making CNS drug development an important area for focus in Japan.